NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Last Close
May 23 04:00PM ET
2.27
Dollar change
-0.20
Percentage change
-8.10
%
IndexRUT P/E- EPS (ttm)-3.37 Insider Own54.75% Shs Outstand43.22M Perf Week-2.16%
Market Cap98.11M Forward P/E- EPS next Y-3.15 Insider Trans0.00% Shs Float19.55M Perf Month6.07%
Income-145.42M PEG- EPS next Q-1.04 Inst Own25.51% Short Float10.93% Perf Quarter-21.72%
Sales0.00M P/S- EPS this Y-11.70% Inst Trans-16.96% Short Ratio7.31 Perf Half Y-44.36%
Book/sh5.18 P/B0.44 EPS next Y15.42% ROA-44.70% Short Interest2.14M Perf Year-83.43%
Cash/sh5.61 P/C0.40 EPS next 5Y-2.34% ROE-49.72% 52W Range1.78 - 16.64 Perf YTD-39.30%
Dividend Est.- P/FCF- EPS past 5Y- ROI-63.96% 52W High-86.36% Beta2.46
Dividend TTM- Quick Ratio7.44 Sales past 5Y-25.27% Gross Margin- 52W Low27.53% ATR (14)0.22
Dividend Ex-Date- Current Ratio7.44 EPS Y/Y TTM-48.62% Oper. Margin- RSI (14)51.76 Volatility12.13% 7.35%
Employees112 Debt/Eq0.03 Sales Y/Y TTM- Profit Margin- Recom1.33 Target Price17.00
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q8.09% Payout- Rel Volume1.80 Prev Close2.47
Sales Surprise- EPS Surprise8.50% Sales Q/Q- EarningsMay 13 AMC Avg Volume292.11K Price2.27
SMA203.44% SMA505.16% SMA200-45.18% Trades Volume524,822 Change-8.10%
Date Action Analyst Rating Change Price Target Change
Oct-10-24Initiated UBS Buy $13
Oct-09-24Initiated Rodman & Renshaw Buy $16
Jul-03-24Initiated H.C. Wainwright Neutral $8
Mar-04-24Initiated Wells Fargo Overweight $44
Mar-04-24Initiated Morgan Stanley Overweight $40
Mar-04-24Initiated Leerink Partners Outperform $48
Mar-04-24Initiated JP Morgan Overweight $39
May-16-25 06:36AM
May-13-25 04:02PM
Apr-17-25 07:38AM
Mar-27-25 04:02PM
Mar-24-25 09:13AM
11:29AM Loading…
Mar-21-25 11:29AM
08:32AM
Mar-18-25 04:48PM
Mar-17-25 03:01PM
Mar-03-25 04:05PM
Feb-10-25 12:00PM
Jan-21-25 04:05PM
Jan-17-25 05:45AM
Jan-13-25 07:30AM
Jan-08-25 08:00AM
05:45AM Loading…
Jan-07-25 05:45AM
Jan-06-25 04:05PM
Dec-27-24 05:45AM
Dec-19-24 12:16PM
Dec-13-24 04:05PM
Dec-09-24 06:38PM
Nov-14-24 10:01AM
Nov-13-24 04:14PM
Oct-21-24 08:00AM
Oct-19-24 11:13AM
Oct-10-24 03:05PM
Sep-18-24 08:00AM
Sep-16-24 08:00AM
06:58AM
Aug-21-24 04:05PM
04:08PM Loading…
Aug-12-24 04:08PM
04:05PM
Jul-16-24 11:33AM
08:52AM
Jul-15-24 04:05PM
Jun-20-24 08:55AM
Jun-17-24 04:05PM
Jun-10-24 04:05PM
Jun-07-24 08:55AM
May-14-24 10:54PM
04:05PM
Apr-11-24 05:01PM
Mar-29-24 02:59PM
Mar-26-24 04:05PM
Mar-14-24 07:00AM
Mar-07-24 07:26PM
06:14PM
Feb-12-24 04:39PM
Feb-07-24 10:29PM
Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Walker Karen MarieChief Technology OfficerJun 06 '24Option Exercise4.429,63642,5919,636Jun 10 06:56 PM
Jones Ryan AlexanderChief Financial OfficerMay 28 '24Option Exercise0.7318,01613,15243,950May 29 04:33 PM